{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T18:43:53Z","timestamp":1777747433855,"version":"3.51.4"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T00:00:00Z","timestamp":1283385600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVE:<\/jats:bold>\n                    To determine the efficacy of a zoster vaccine on herpes zoster (HR)\u2010related interference with activities of daily living (ADLs) and health\u2010related quality of life (HRQL).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    Randomized double\u2010blind placebo controlled trial.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    Twenty\u2010two U.S. sites.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PARTICIPANTS:<\/jats:bold>\n                    Thirty eight thousand five hundred forty\u2010six women and men aged 60 and olcer.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS:<\/jats:bold>\n                    HZ burden of interference with ADLs and HRQL using ratings from the Zoster Brief Pain Inventory (ZBPI) and Medical Outcomes Study 12\u2010item Short Form Survey (SF\u201012) mental component summary (MCS) and physical component summary (PCS) scores. Vaccine efficacy was calculated for the modified\u2010intention\u2010to\u2010treat trial population and solely in participants who developed HZ.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    For the modified\u2010intention\u2010to\u2010treat population, the overall zoster vaccine efficacy was 66% (95% confidence interval (CI)=55\u201374%) for ZBPI ADL burden of interference score and 55% (95% CI=48\u201361%) for both the SF\u201012 MCS and PCS scores. Of participants who developed HZ, zoster vaccine reduced the ZBPI ADL burden of interference score by 31% (95% CI=12\u201351%) and did not significantly reduce the effect on HRQL.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSIONS:<\/jats:bold>\n                    Zoster vaccine reduced the burden of HZ\u2010related interference with ADLs in the population of vaccinees and in vaccinees who developed HZ. Zoster vaccine reduced the effect of HZ on HRQL in the population of vaccinees but not in vaccinees who developed HZ.\n                  <\/jats:p>","DOI":"10.1111\/j.1532-5415.2010.03021.x","type":"journal-article","created":{"date-parts":[[2010,9,14]],"date-time":"2010-09-14T15:45:07Z","timestamp":1284479107000},"page":"1634-1641","source":"Crossref","is-referenced-by-count":90,"title":["Effect of a Zoster Vaccine on Herpes Zoster\u2013Related Interference with Functional Status and Health\u2010Related Quality\u2010of\u2010Life Measures in Older Adults"],"prefix":"10.1111","volume":"58","author":[{"given":"Kenneth E.","family":"Schmader","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Saddier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ciarleglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.B.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan S.F.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shing\u2010Shing","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron J.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth M.","family":"Harbecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Oxman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Shingles Prevention Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,2]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"9","article-title":"The nature of herpes zoster","volume":"58","author":"Hope\u2010Simpson RE.","year":"1965","journal-title":"A long-term study and a new hypothesis"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e318065b6c9"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/320884"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/421942"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"e_1_2_6_7_2","first-page":"344","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials","volume":"5","author":"Coplan PM","year":"2004","journal-title":"Adaptation of the brief pain inventory"},{"key":"e_1_2_6_8_2","first-page":"129","article-title":"Pain assessment","volume":"23","author":"Cleeland CS","year":"1994","journal-title":"Global use of the brief pain inventory"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00435221"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00439226"},{"key":"e_1_2_6_11_2","first-page":"220","article-title":"A 12\u2010item short\u2010form health survey","volume":"34","author":"Ware J","year":"1996","journal-title":"Construction of scales and preliminary tests of reliability and validity"},{"key":"e_1_2_6_12_2","unstructured":"NorquistJ NikasA SaddierPet alMeasuring aspects of daily life in patients with herpes zoster. Abstract. International Society for Quality of Life Research 12th Annual Conference San Francisco CA. October 2005."},{"key":"e_1_2_6_13_2","unstructured":"Food and Drug Administration.Zostavax Package Insert [on\u2010line]. Available at:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM132831.pdfAccessed March 21 2010."},{"key":"e_1_2_6_14_2","unstructured":"Food and Drug Administration.Zostavax (Herpes Zoster Vaccine) Questions and Answers [on\u2010line]. Available at:http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/QuestionsaboutVaccines\/ucm070418.htmAccessed March 14 2010."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-9-201005040-00004"},{"key":"e_1_2_6_16_2","first-page":"S21","article-title":"Safety and tolerability of zoster vaccine in adults \u226560 years old","volume":"58","author":"Murray AV","year":"2010","journal-title":"J Am Geriatr Soc"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-5415.2010.03021.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-5415.2010.03021.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:40:35Z","timestamp":1762173635000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-5415.2010.03021.x"}},"subtitle":["[See editorial comments by Dr. Roy Fried, pp 1799\u20101800]"],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1532-5415.2010.03021.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-5415.2010.03021.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}